Recent changes
GovPing tracks 141 sources for this role out of 2,348 total sources on GovPing, covering Guidance, Enforcement, Rule, Notice, and Consultation instruments. There were 722 changes in the last 7 days.
Health Canada issued a Type I recall for nitrous oxide chargers sold by DOODELZ, Gold Whip, and Whip-it! brands without market authorization, while the UK VMD called for a Class II recall of Zoetis's Scabigard Suspension for cutaneous administration. FDA classified Draeger's Atlan A350 anesthesia workstations as a Class I recall due to potential piston ventilator failure, and Morovan recalled approximately 4,000 units of Gel Nail Polish Remover for methylene chloride and chloroform contamination.
Merck TLR7/8 antagonist patent for coronavirus
Merck TLR7/8 antagonist patent for coronavirus
Anti-TMPRSS6 Antibodies Patent by Mabwell Therapeutics
EPO granted Mabwell Therapeutics Inc. Patent EP4126220A1 for anti-TMPRSS6 antibodies covering therapeutic uses including treatment of conditions such as anemia. The patent application EP4126220 lists inventors DU Xin, CHEN Buxin, and WANG Yu Jean. The designated states cover 31 European Contracting States including DE, FR, GB, IT, ES, and others.
Treatment for Depression with Positive Allosteric Modulator of AMPA
The European Patent Office published patent application EP4149478A1 for Takeda Pharmaceutical Company Limited, covering a treatment for depression using a positive allosteric modulator of AMPA (AMPA receptor). The patent was published on April 1, 2026, with inventors including Pathi Jagannatham, Naga Venkatesha Murthy, Asgharnejad Mahnaz, and Xu Lin. The designated states include 27 European countries covering major pharmaceutical markets.
European Patent for Tesofensine Treating Hypothalamic Obesity
EPO published patent application EP4138830A1 by Saniona A/S covering the use of tesofensine for treating hypothalamic obesity. The patent is classified under A61K 31/46, A61K 45/06, A61P 3/04, and designates 38 European states including DE, FR, GB, IT, ES, NL, SE, and others. Inventors include DREJER Jørgen, KROGSGAARD Kim, and EDBERG Berit.
Hydroxyureamethyl Acylfulvene for Treating Brain Cancer or CNS Cancer
The European Patent Office published patent EP4132489A1 on April 1, 2026, granting Lantern Pharma Inc. exclusive rights to hydroxyureamethyl acylfulvene for treating brain cancer or CNS cancer. The patent names inventors Kulkarni and Bhatia and covers the compound, formulations, and methods of treatment using the drug. This provides Lantern Pharma with patent protection in 34 EPC contracting states for 20 years from the filing date.
Phosphate-containing copolymers for virulence suppression
The European Patent Office published patent application EP4182377A1 for 3M Innovative Properties Company's phosphate-containing copolymers designed to suppress bacterial virulence. The invention covers copolymer compositions targeting A61P 31/04 (anti-infectives). Designated states cover all EU member states plus additional European countries.
Rituximab and cladribine sequential treatment in early MS
Rituximab and cladribine sequential treatment in early MS
Projected Reality variance application, FDA, California, Apr 8
Projected Reality variance application, FDA, California, Apr 8
Study NCT07516483 content unavailable
The National Institutes of Health's ClinicalTrials.gov registry has marked study NCT07516483 as unavailable, indicating the trial record cannot be accessed. This status update reflects that the registration details, results, and participant information for this specific trial are currently inaccessible to the public. Researchers, sponsors, and stakeholders monitoring this trial should be aware that no public-facing information exists in the registry for this NCT number.
IMIPAT Study - Parathyroid Tissue Injection - Medical University of Vienna
ClinicalTrials.gov registered a new interventional study (NCT07516990) conducted by the Medical University of Vienna investigating parathyroid tissue injection. The Phase 1 study is listed as actively recruiting and will evaluate safety and preliminary efficacy outcomes in human subjects.
Get daily alerts for pharma & life sciences
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
737 changes in last 7 days
Latest high priority updates
142 official sources tracked
Frequently asked questions
What does this feed cover?
FDA warning letters, novel drug approvals, drug shortage notices, ICH guideline updates, USP notices, EMA news, DEA scheduling decisions, and TGA/WHO standards.
Who is this for?
Regulatory affairs professionals, pharmacovigilance teams, and medical affairs groups at pharma companies and CROs who need to track FDA and EMA actions.
How often is this updated?
GovPing checks source pages multiple times daily. FDA warning letters and drug approvals typically appear within hours of publication.
Does this cover EMA and international regulators?
Yes. We monitor the EMA, ICH, WHO, TGA (Australia), and other international health authorities alongside FDA.
How is this different from AgencyIQ?
AgencyIQ is a full FDA intelligence platform. GovPing is a free feed of the FDA, EMA, and ICH source pages where warning letters, approvals, drug shortages, and guidance are first published - AI-summarized with attention-level ratings on every change.
Is GovPing free?
Yes. GovPing is free, and always will be. We believe government regulatory data should be accessible to everyone. For custom monitoring of pages we don't cover yet, Changeflow starts at $99/mo.
Need to monitor something else?
GovPing covers the common sources. For niche pages specific to your team, add custom URL monitoring with Changeflow.
Get Pharma & Life Sciences alerts
Daily digest of pharma & life sciences regulatory changes. AI-summarized, no noise.
Free. Unsubscribe anytime.